https://www.selleckchem.com/pr....oducts/zasocitinib.h
Background Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observation randomised trials demonstrated that a treatment benefit was observed only in patients with an ulcerated melanoma without palpable nodes (hazard ratio [HR] for recurrence-free survival [RFS] was 0.69). This was confirmed by a meta-analysis of 15 adjuvant IFN trials (HR 0.79). Patients and methods In the EORTC 18081 trial, sentinel node-negative stage II patients with an ulcerated primary melanoma were 11 randomised between pegylated (
Like
Comment
Share
